Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (356)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06620510 | Retrospective Study of Long-Term Survival of "Immuncell-LC" in Patients Undergoing Curative Resection for HCC in Korea | completed | — | 230 | GC Cell CorporationINDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT04791176 | Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | completed | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 14, 2025 |
| clinicaltrials |
| NCT05616039 | I-FIGS Feasibility Study(I-FIGS) | completed | N/A | 42 | University Hospital Plymouth NHS TrustOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT01356628 | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | completed | Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06156748 | CT Imaging for Guiding PA-TACE for HCC | completed | — | 1,770 | Zhujiang HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04069468 | Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)(PROACTIF) | completed | — | 1,247 | Boston Scientific CorporationINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05101629 | Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy | completed | Phase 2 | 32 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07075562 | TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion | completed | N/A | 180 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02312817 | RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System | completed | N/A | 1,800 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT02940496 | Pembrolizumab (MK-3475) in Hepatocellular Carcinoma | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT07053202 | TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma | completed | N/A | 140 | The First Hospital of Hebei Medical UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT01628640 | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors | completed | Phase 1 | 17 | Mayo ClinicOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03781934 | A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations | completed | Phase 1 / Phase 2 | 53 | MedivirINDUSTRY | 4 | Jul 1, 2025 | clinicaltrials |
| NCT07030842 | Precision Recurrence Risk Assessment in Early-stage Hepatocellular Carcinoma | completed | — | 579 | Tongji HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05635279 | Effect of Nutritional Indices on the Prognosis of HCC Patients | completed | — | 150 | Juan KangOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06991907 | PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety | completed | N/A | 80 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04611165 | Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC(Nextrah) | completed | Phase 2 | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | May 22, 2025 | clinicaltrials |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | completed | Phase 3 | 131 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05750030 | FMT in IT-refractory HCC - FAB-HCC Pilot Study | completed | Phase 2 | 12 | Medical University of ViennaOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT01754987 | A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | completed | Phase 1 / Phase 2 | 5 | Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03045497 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT01349075 | TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma | completed | — | 474 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT04720430 | Blood Sample Collection for Experimental Blood Test to Track Liver Cancer | completed | — | 7 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03783871 | NeuWave Microwave Ablation HCC China Study(NW) | completed | N/A | 135 | Ethicon, Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06092112 | A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma | completed | Early Phase 1 | 2 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT06544005 | Implication of Long Non-coding RNA HOTTIP Haplotype on Liver Cancer Metastasis | completed | — | 198 | Ain Shams UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03507140 | Microbiota Study in Liver Transplanted Patients(BIM-LT) | completed | — | 64 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
| NCT02234986 | A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | completed | Phase 2 | 35 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04000737 | YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 62 | Yiviva Inc.INDUSTRY | 4 | Apr 13, 2025 | clinicaltrials |
| NCT06916546 | SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC | completed | — | 238 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04316182 | Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION)(ACTION) | completed | Phase 2 | 24 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06899763 | Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy(1003rcr2022_72) | completed | — | 6 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06416683 | Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)(ABCHCaen) | completed | — | 109 | University Hospital, CaenOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06503250 | A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | completed | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04484636 | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)(PLATON) | completed | N/A | 400 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05250895 | BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy | completed | Early Phase 1 | 9 | Emory UniversityOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04401800 | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma | completed | Phase 2 | 64 | BeiGeneINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04710641 | Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone(OUTREACH2) | completed | Phase 2 | 8 | Mina Alpha LimitedINDUSTRY | 2 | Mar 6, 2025 | clinicaltrials |
| NCT05233098 | TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. | completed | — | 6 | Boston Scientific CorporationINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04297280 | TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT02905188 | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)(GLYCAR) | completed | Phase 1 | 9 | Baylor College of MedicineOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04948697 | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC | completed | Phase 2 | 94 | BeiGeneINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT04022746 | An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer | completed | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06037343 | Deep Learning Image Reconstruction for Abdominal CT of Hepatocellular Carcinoma Compared With 3-TESLA MRI | completed | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02576509 | An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma | completed | Phase 3 | 743 | Bristol-Myers SquibbINDUSTRY | 22 | Feb 17, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 15, 2025source: clinicaltrials